openPR Logo
Press release

Digitized transience to drive the Biologics Contract Manufacturing Demand Market

01-17-2022 05:28 AM CET | Health & Medicine

Press release from: Persistence Market Research

Digitized transience to drive the Biologics Contract

The Biologics Contract Manufacturing Demand Market is likely to grow on a robust note in the next decade. The next decade would be seeing the integration of telehealth services with the physical ones that exist at the moment. Urgent care and primary care are bound to be accessed through virtual visits, along with improvement in collaboration with the clinics, dialysis centres, long-term care facilities, and mental health services. This shifting is to be witnessed in the healthcare vertical shortly.
Pharmaceuticals and biotechnology companies are outsourcing specific services from the early stages of drug development to biological contract manufacturing organizations to reduce drug manufacturing costs. Outsourcing increases drug manufacturing efficiency and facilitates flexible operational capabilities, which is expected to immensely boost biologics contract manufacturing demand. Rising prevalence of chronic and lifestyle diseases is also anticipated to propel biologics contract manufacturing demand. Besides, continuous focus by manufacturers toward adopting technologically-advanced systems to manufacture novel biologics is also expected to accelerate the demand for biologics contract manufacturing over the forecast period.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/31928

Global biologics contract manufacturing demand is expected to reach at 8 Mn liters (MnL) in 2030, exhibiting an impressive CAGR of over 17% during the forecast period (2020 – 2030).

Company Profiles:

BioXcellence (Boehringer Ingelheim GmbH)
Lonza Group AG
Samsung Biologics Co. Ltd.
Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
AbbVie Contract Manufacturing (AbbVie Inc.)
WuXi Biologics (Cayman) Inc.
Patheon N.V. (Thermo Fisher Scientific Inc.)
Emergent BioSolutions Inc.
AGC Biologics
Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
Avid Bioservices, Inc.
KBI Biopharma (JSR Life Sciences (JLS))
Catalent Inc.
Abzena Plc.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/31928

Key Takeaways from Biologics Contract Manufacturing Demand Study

Leading global CDMOs are focusing on expansion of their manufacturing capabilities with high flexibility and rapid operation capacity as biologics contract manufacturing demand is high. With the help of advanced single-use technologies, companies are able to cut batch manufacturing and cleaning time from 7 days to 1 day. This trend is expected to provide a competitive-edge to companies in terms of capacity, cost, convenience, and operational efficacy.
For instance, in Oct 2018, Thermo Fisher Scientific Inc. announced a US$ 50 million (€44 million) expansion at a CDMO plant in St Louis, Missouri, U.S., to add 16,000 L of single-use capacity due to extremely strong growth in demand for commercial biologic manufacturing. As per the company, the facility will be the largest outsourced single-use biologics site in North America.
With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. This trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical therapeutic developers.

Get a Customized Scope to Match Your Need Ask an Expert- sales@persistencemarketresearch.com

For example, in July 2020, Avid Bioservices and Argonaut Manufacturing Services entered into an agreement to offer biotechnology and pharmaceutical clients integrated process development, drug substance manufacturing, and drug product parenteral manufacturing, to accelerate the development and commercialization of biopharmaceutical therapeutics.
Viral vector and vaccines contract development and manufacturing services are expected to gain significant traction due to the COVID-19 pandemic breakout and subsequent vaccine development programs.
For instance, in June 2020, AGC Biologics expanded its development capacities for pDNA services at the Heidelberg site, Germany, to meet the growing need for process development and manufacturing for plasmid DNA (pDNA).
Europe is expected to be the most lucrative region and with a revenue share of around one-third in global biologics contract manufacturing demand in 2020, owing to the presence of leading CDMO facilities in the region.
“Technological advancements to improve the manufacturing efficiency of biologics at low cost is expected to flourish market growth opportunities and provide a competitive advantage to market players in terms of innovation,” says a PMR analyst.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/31928

Doubling Industry Capacity by 2022-2023 amid COVID-19 Pandemic

The COVID-19 pandemic is becoming an industry changing milestone by providing opportunities to global CDMOs – small as well big CDMO companies. Local government and industry funds are being targeted toward rapid expansion of industry capacity in order to meet the unmet demand for vaccine development and commercialization amid the COVID-19 crisis.

For instance, in June 2020, Fujifilm Diosynth Biotechnologies announced the investment of 100 billion Yen (US$ 928 Million) to expand its large-scale biologics production facility in Denmark.

Expansion of Manufacturing Capacity – Imperative Strategy for Market Players

Key players involved in biologics contract manufacturing are looking forward to expand their manufacturing capacities to meet global demand. Leading companies are expanding their production capabilities and capacities to become the preferred choice for innovative biopharmaceutical companies and hold on to a strong position in the market.

For instance, in January 2019, Boehringer Ingelheim Biopharmaceuticals China expanded its commercial manufacturing capacities. The company installed an additional bioreactor, all needed utility, and infrastructure for GMP operations.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on biologics contract manufacturing demand in its latest study, presenting historical demand assessment of 2015 – 2019 and projections for 2020 – 2030, on the basis of platform (mammalian and microbial), application (commercial and clinical) product (monoclonal antibodies, recombinant proteins, vaccines, insulin, interferons, growth factors, and others), and therapeutic area (oncology, autoimmune disease, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorders, and others), across seven key regions.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/biologics-contract-manufacturing-demand.asp

Read More Trending "PMR Exclusive Article"-

Immunooncology Market@ https://www.persistencemarketresearch.com/market-research/immunooncology-market.asp

Ineffective Esophageal Motility Treatment Market@ https://www.persistencemarketresearch.com/market-research/ineffective-esophageal-motility-treatment-market.asp

Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About us-
Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Digitized transience to drive the Biologics Contract Manufacturing Demand Market here

News-ID: 2528232 • Views:

More Releases from Persistence Market Research

Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Frozen Foods Market Heats Up with Innovation and Growing Consumer Demand
Market Overview: The frozen foods market consists of a wide range of products, including frozen fruits and vegetables, meat and seafood, ready-to-eat meals, and desserts. These products are preserved through freezing to maintain freshness and quality for an extended period. Market Size and Growth: The global market for frozen foods is forecasted to be of valuation US$ 281.0 Billion in the year 2022 which is expanding at a value CAGR of 5.1% and
The Global Graphene Market's Striking Growth and Innovative Applications
The Global Graphene Market's Striking Growth and Innovative Applications
Introduction Graphene, a single layer of carbon atoms arranged in a hexagonal lattice, has gained global recognition for its extraordinary properties, such as exceptional electrical and thermal conductivity, mechanical strength, and flexibility. Since its isolation in 2004 by Andre Geim and Konstantin Novoselov, graphene has sparked considerable interest in both scientific and industrial communities. This report explores the current state of the graphene market and its potential growth opportunities. Get Access To
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analysis, Emerging Trends with Upcoming Developments
Business Opportunities in Cyber Security Mesh Market : Top Countries Data Analys …
Market Overview: The projected global market size for cyber security mesh is expected to reach $8.8 billion by the year 2033, with an estimated valuation of $1.2 billion by 2023. This market is poised to experience a compound annual growth rate (CAGR) of 21.7% from 2023 to 2033. The global Cyber Security Mesh market is poised for significant growth as organizations worldwide grapple with the escalating threat landscape. Cybersecurity has become an
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation and Industry Size
Synthetic Beta-Carotene Market To Boost Incredible Growth: 2033, Share Valuation …
Key market trends included a shift towards natural and plant-based ingredients, as consumers sought cleaner labels and healthier options. This drove the demand for naturally sourced beta-carotene, but synthetic beta-carotene still had its place due to its cost-effectiveness and consistency in production. The market was also influenced by regulatory changes and evolving dietary preferences, which affected the application and formulation of synthetic beta-carotene in various products. To obtain the latest market

All 5 Releases


More Releases for Biologics

Biopharmaceutical CMO Market 2020 Business Scenario – Lonza, Boehringer Ingelh …
The report provides a valuable source of insightful data for business strategists and competitive analysis of Biopharmaceutical CMO Market. It provides the Biopharmaceutical CMO industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This Tire Biopharmaceutical CMO study provides comprehensive data which enhances the understanding, scope and application of this report. the
Extracellular Matrix Market Detailed Analysis 2020: Top Companies like Coloplast …
The global extracellular matrix market by raw material segments was led by porcine segment. In 2018, the porcine segment held a largest market share of 41.09% of the extracellular matrix market, by raw material. However, the bovine segment is expected to be the fastest growing segments of the market in 2027 owing to more beneficial properties to treat various conditions which is expected to become the major factor for the
Biopharmaceutical CMO Market 2018-2023 :Lonza, Boehringer Ingelheium, Samsung Bi …
Global Biopharmaceutical CMO Industry - A Global Market Overview (2018-2023) (Avail A 10% Off) The "Global Biopharmaceutical CMO Market Research Report 2018-2023" is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides
Global Biopharmaceutical CMO Market Key Profiles - Wuxi Biologics, Boehringer In …
Global Biopharmaceutical CMO Market was valued at USD 13296.29 million in the year 2019. Escalating number of patients suffering from various diseases with growing investment in the healthcare industry by government in major economies and increasing awareness among consumers regarding impact of various viruses on health, has been anticipated to infuse growth in the market for Biopharmaceutical CMO during the forecasting period of 2020-2025. Get Free Sample Copy of this Research
Plant-based Biologics
Increasing demand for biologics for various chronic diseases and rising investment in R&D for the production of biologics is expected to contribute significantly to the growth of plant-based biologics market. According to Biotechnology Innovation Organization (BIO) 2015, over 250 biologic therapies and vaccines have changed the lives of hundreds of millions of patients. Moreover, according to the same source, over 900 biologics are currently (2018) under the stage of development
Global Biopharmaceutical CMO Market 2018-2023| Lonza, Boehringer Ingelheium, Sam …
Albany, NY, 10th September : Recent research and the current scenario as well as future market potential of "Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) - By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)" globally. A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to